The World Health Organization (WHO) is celebrating the Immunization Week with the main goal of promoting vaccination to protect people at all ages from diseases. Since Jenner invented the first vaccine against smallpox at the end of XVIII century, the progresses in the prevention area have saved millions of lives worldwide and they will continue doing it in the future.

According to the WHO, immunization Immunization averts an estimated 2 to 3 million deaths every year from diphtheria, tentanus, whooping cough and measles. Other preventable diseases through vaccination are meningitis, hepatitis B, mumps, poliomyelitis and rubella, among others. Although the immunization coverage is higher and higher in the world, there are still a lot of challenges to achieve. The same institution shows that around 18.7 million of breast-fed babies worldwide in 2014 were not covered by the system of vaccination, because of that it is necessary to double efforts.

Further information about immunization coverage (WHO)

Vaccination is one of the mainstays of the preventive medicine, being the flagship for Medicine at the XXI century. Immunization is a broad field of scientific research for human and animal health. Bionaturis, an international benchmark in the development of biologic vaccines for both sectors, is working in this sphere of knowledge. With the main goal of putting ultimate health technologies and products at a more global reach of customers and users, Bionaturis has developed its alternative platform to produce biological products, FLYLIFE, that offers flexibility, high scale-up speed and less demand of space and investment. Bionaturis has a rich portfolio of biologic products as a vaccine against visceral canine leishmaniosis, another one against nematodes in livestock and other vaccines that prevent several diseases in birds, swines and fish in aquaculture. About human health, the company is taking part in a vaccine against human common cold and another one against the spread of the Human Papillomavirus (the main cause of cervical cancer).

Fighting against emerging and re-emerging diseases

The scientific research in immunization is essential in the case of emerging and re-emerging diseases –for both human and animal health- which have in the vaccination its main tool to avoid its spread. Experts have alerted that phenomena such as the climate change and the increase of population and its needs of food, among others, are stimulating the spread of diseases that require more preventive resources.

Due to our interconnected world, animal health, environment and human health are more and more linked. Considering that 60% of infectious diseases suffered by human come from domestic or wild animals (according to the World Organisation for Animal Health), the collaboration between different sectors and experts around the initiative ‘One World, ‘One Health’ is crucial. In this sense, the immunization of pets and livestock is especially relevant to avoid zoonotic outbreaks.

Further information about this worldwide initiative

Prevention against antibiotic resistances

Phenomena such as the antibiotic resistances – that could cause until 300,000 deaths in Europe and the USA each year- turn the research in new preventive alternatives into a more and more necessary issue. In this sense, Bionaturis is taking part, along with other companies, in the ADELIS project with the goal of reducing the use of antibiotics in animal health that could contribute to generate resistances both in animals and, in a long term, in humans. In particular, Bionaturis addresses the problem by a pioneering approach proposing a collection of antimicrobial peptides, some of them produced by the FLYLIFE system that will be tested in animal models using cutting-edge drug delivery systems originated from ADELIS.

About Bionaturis

Bionaturis Group offers cutting-edge biotechnological drugs and services for human and animal health. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the Spanish stock exchange for SMEs (ticker BNT).